Your ally in the race against cancer

Transform uncertainty into clarity with Veracyte cancer tests

Our high-performing molecular tests empower clinicians and their patients with important information that has helped guide care decisions for over 800,000 people.

Explore Technology Find a Test

How we help guide cancer care

Our tests assess the unique biology of each patient’s tumor. This helps clinicians answer key questions and make confident decisions for thyroid, prostate, breast, bladder, and lung cancer. The important information from our tests helps enable personalized and effective patient care.

Two friends walking on a beach, smiling and embracing, with the ocean in the background. The scene conveys warmth, companionship, and joy.

PRESS RELEASE

Decipher Prostate Metastatic test now available for patients with metastatic prostate cancer in the US.

Learn More

We’re here to support your journey

Find the information most relevant to you.

Market-leading cancer tests backed by evidence1

>800K

Patients benefited from our genomic tests across multiple cancer types

Explore Technology

>600

Peer-reviewed publications validate our platform’s clinical utility

View Publications

>35

Phase 2 & 3 trials evaluating our tests

Explore Clinical Studies

Did You Know?

Decipher Prostate Genomic Classifier

is the only gene expression test included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer2

Explore

Real impact on patient care

patient with daughter

I knew there was another genomic test that could provide this information, but I specifically requested the Prosigna test because I wanted to be sure of the accuracy for guiding my treatment decisions.”1

Patient testimonial (pictured with her daughter) Prosigna Breast Risk of Recurrence Test
A Veracyte Afirma patient photo

The Afirma test saved me from a big change in my life and the joy of what I have gotten to keep is to continue having music in my life, to continue teaching at the highest level I can, which is to be able to use my voice when I’m teaching. The Afirma test was like a safety net, and I can go on with my life.”1

Patient testimonial Afirma Genomic Sequencing Classifier

Veracyte Diagnostics Platform

A powerful evidence-generation engine that delivers diagnostic innovation.

Explore Our Platform

More data

Transcriptomes, genomes, complementary data sources, and clinical outcomes

More utility

For current tests and new cancer applications

More evidence

From the analysis of real-world data and clinical studies

More insights

From AI-assisted data mining, multimodal analysis, and bioinformatics analysis

Veracyte Diagnostics Platform

Latest from Veracyte

Every breakthrough brings us closer to improved outcomes for those touched by cancer. Explore our latest updates, news, and insights.

Press Release | March 2026

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Read

Press Release | February 2026

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Read

On-Demand Webinar | Now Available

Tumor-Informed Whole-Genome ctDNA Profiling: Transforming MRD and Biomarker Strategy in Oncology Trials

Watch Today

Research Collection | Free Download

Afirma 2025 Research Collection

Download Now

Blog Article | October 2025

The need to fight breast cancer has never been greater

Read

Meet #TeamVeracyte, making a difference for patients globally

We value a diverse, inclusive workplace where creativity, collaboration, and compassion thrive. Our team members are empowered to lead discoveries that are changing the future of cancer care, with positions in state-of-the-art labs, offices, field locations, and remote work.

Explore Job Openings Working at Veracyte Cancer Diagnostic Labs

Let’s connect

Contact Us Today

References

  1. Veracyte, Inc. Company data on file. Updated March 2026.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.5.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed March 12, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.

Disclaimers

Decipher testing is available in the United States as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service, and FDA clearance is not required.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.